News

The companies will integrate the Genialis Supermodel with Inventia’s RASTRUM 3D cell model platform to study pancreatic ductal adenocarcinoma (PDAC) and test therapeutic hypotheses. Initial findings from the

S32 led the oversubscribed financing round. Investors included Catalio Capital Management, European Tech Collective, and Firebrand River Capital. Other backers were Nvidia, PostScriptum, Redalpine, The Rockefeller Foundation, Singular,

The agreement includes an upfront payment, as well as potential development, regulatory, and sales milestone payments for BoomRay, along with possible royalties on future global net sales. The

Under the agreement, Envisagenics is set to receive more than $1bn through potential payments. These include an upfront sum, research funding, option fees, and milestones related to commercialisation,

The company said programmes could be onboarded at the facility immediately, rather than after a construction and qualification period, with the site intended to support clinical and commercial

The authorisation allows both treatments to be used for patients with primary hypercholesterolaemia, including those with heterozygous familial and non-familial forms or mixed dyslipidaemia. This is said to

The Australian company will pay $1.65bn upfront on a cash-free, debt-free basis. An additional $700m may be payable if ITM-11 meets specified regulatory approval and sales milestones. The

The candidate is in early-stage development and references Hemlibra (emicizumab), a medicine used to treat patients with haemophilia A. The companies said the reference medicine has estimated global

The deal grants Ona Therapeutics rights to develop the ADC targeting a single undisclosed target. It includes an upfront payment from Ona Therapeutics to WuXi XDC, along with